• Dorian Yarih Garcia-Ortega, Karla Susana Martín-Tellez, Mario Cuellar-Hubbe, Héctor Martínez-Said, Alethia Álvarez-Cano, Moises Brener-Chaoul, Jorge Adán Alegría-Baños, and Jorge Luis Martínez-Tlahuel.
• National Cancer Institute (Instituto Nacional de Cancerologia), Mexico City 14080, Mexico.
• Cancers (Basel). 2020 Jul 9; 12 (7).

AbstractDesmoid tumors represent a rare entity of monoclonal origin characterized by locally aggressive behavior and inability to metastasize. Most cases present in a sporadic pattern and are characterized by a mutation in the CTNNB1 gene; while 5-15% show a hereditary pattern associated with APC gene mutation, both resulting in abnormal β-catenin accumulation within the cell. The most common sites of presentation are the extremities and the thoracic wall, whereas FAP associated cases present intra-abdominally or in the abdominal wall. Histopathological diagnosis is mandatory, and evaluation is guided with imaging studies ranging from ultrasound, computed tomography or magnetic resonance. Current approaches advocate for an initial active surveillance period due to the stabilization and even regression capacity of desmoid tumors. For progressive, symptomatic, or disabling cases, systemic treatment, radiotherapy or surgery may be used. This is a narrative review of this uncommon disease; we present current knowledge about molecular pathogenesis, diagnosis and treatment.

5 keywords...

hide…